Alkem’s MedTech Arm to Acquire 55% of Occlutech
Alkem Laboratories said its medical devices subsidiary will acquire up to a 55% stake in Switzerland-based Occlutech Holding AG for 99.4 million euros (about $118 million), marking its entry into advanced cardiovascular devices. The transaction, expected to close by June 2026 subject to regulatory approvals and final agreements, will expand Alkem MedTech’s presence in high-value markets including the United States, Japan, Germany and other Western European countries.
Occlutech is the second-largest player in Europe’s minimally invasive cardiac implants segment and reported revenue of 49.4 million euros in 2025, with nearly 85% of its sales coming from Europe and the U.S. The acquisition positions Alkem to tap into the fast-growing global medical devices market, which industry estimates project will exceed $1 trillion by 2034.
Separately, Alkem reported third-quarter consolidated net profit of ₹6.36 billion, slightly below analyst estimates, while revenue rose nearly 11% year-on-year to ₹37.37 billion but missed expectations. Shares of the company ended 8% lower following the announcement.
Pic courtesy: google/ images are subject to copyright
